SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant drop, driven by the expiration of a lock-up period, making a large number of shares available for sale; the community is debating whether this presents a buying opportunity or signals deeper issues, with some pointing to potential insider selling and comparing it to other struggling fintech companies. The high trading volume and price volatility are fueling discussions about potential manipulation and future prospects.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending after announcing a commercial agreement with Verizon for satellite-to-phone service by 2026, building on their existing partnership and sparking considerable excitement. The community is buzzing about the potential for seamless nationwide coverage and the stock's impressive gains, while also debating the impact of a recent stock offering and analyst ratings. Many express long-term bullish sentiment, viewing ASTS as a visionary play in the evolving space-based cellular connectivity sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent $75 million investment, fueling speculation about the investor and its implications for the company's growth in AI connectivity. The community is focused on POET's potential in chip-to-chip communication and its role in addressing bottlenecks within AI data centers, viewing it as a key player in the broader AI hardware ecosystem.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its potential for a short squeeze, driven by high short interest and recent positive news around AI adoption in the insurance sector. Community members are actively debating entry and exit points, with many expressing bullish sentiment and anticipating a move towards higher price targets. The stock's technicals and potential for disruption in the voice AI space are also fueling the conversation.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending as traders discuss its low float and substantial cash reserves, speculating on potential buybacks or strategic moves. The community is watching for news, especially regarding potential cryptocurrency ventures, that could drive the price higher. Some are comparing it to other recent low-float bio stock runners, anticipating a similar breakout.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss recent price volatility and potential short squeezes after news of the company's tokenization plans and a closed financing round. Traders are actively debating the stock's momentum, with some pointing to the company's low float and crypto-related initiatives, while others warn of potential pump-and-dump schemes. The conversation includes speculation about upcoming catalysts and potential for both significant gains and losses.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Xenetic Biosciences Inc

XBIO is trending as traders discuss the potential for another short squeeze, drawing comparisons to other recent high-flying low float biotech stocks. Community members are actively speculating on potential price targets and entry points, while also noting the company's expanded R&D collaboration with The Scripps Research Institute. Some caution against FOMO (fear of missing out) and highlight the stock's volatility.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

RNAZ is trending due to its recent acquisition of Polynoma and a secured $25 million financing, viewed as a significant catalyst despite potential dilution concerns. Community discussions revolve around the company's low float and potential for a squeeze, with some highlighting its cancer treatment advancements. The stock's volatility and upcoming Phase 2 trial are also key talking points.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

AREB is trending due to a proposed reverse stock split with a unique "round lot protection" clause, sparking mixed reactions; some see it as a buying opportunity, while others fear dilution. Community discussions revolve around the mechanics of the split, its potential impact on share value, and whether it's a strategic move or a sign of underlying issues. Speculation about short squeezes and potential for gains/losses is rampant amid the volatility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending after securing new commercial orders and receiving a price target increase, fueling both bullish sentiment and skepticism about its valuation. Community chatter highlights concerns about a potential offering, while others believe the stock's upward trajectory is just beginning. The debate centers on whether RGTI's current price reflects its future potential in the quantum computing sector or if it's experiencing a speculative bubble.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting...

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025...

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent...

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire NEW YORK, Jan. 17, 2025 NEW YORK, Jan. 17...

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire NEW YORK, Jan. 8, 2025 The Company affirms...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges.&nbsp;Trading volume skyrocketed to 665 times its daily average, driven by positive interim data from its Phase 2a trial of HT-001, a therapy targeting skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors in cancer patients.The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.&nbsp;Additionally, 66% of patients reported reduced pain and itching, improving their quality of life without any treatment-related adverse effects, the company said.CEO Robb Knie described the results as a “significant milestone,” emphasizing the potential of HT-001 to alleviate debilitating skin conditions while enabling patients to continue life-saving cancer treatments.D. Boral Capital echoed this optimism, highlighting the therapy’s potential to revolutionize care for patients enduring severe side effects from cancer treatments.&nbsp;The brokerage reiterated its ‘Buy’ rating and maintained a $5 price target on Hoth’s shares, implying a near doubling from current levels.Retail investors on Stocktwits rallied behind the news, with chatter indicating overwhelmingly bullish commentary.&nbsp;One user predicted a further surge to $10, urging users to “buy cheap now.”&nbsp;<stembedurl>https://stocktwits.com/Aone7Prof/message/599175761</stembedurl>Another emphasized the company’s strong position, pointing out its debt-free status and cash reserves.<stembedurl>https://stocktwits.com/Millionaire2/message/599174136</stembedurl><stembedurl>https://stocktwits.com/JBG99/message/599173146</stembedurl>Hoth’s pipeline includes therapies for dermatological disorders such as eczema, psoriasis, chronic wounds, and acne.&nbsp;The company’s stock has gained nearly 80% over the past year.The successful Phase 2a trial positions Hoth to attract interest from larger players in the oncology and dermatology sectors.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited 

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.

Equity

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.


Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001...

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop...

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire NEW YORK, Nov. 20, 2024 NEW...

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway Hoth Therapeutics Awarded Key US Patent for...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Hoth Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

HOTH Hoth Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HOTH News